

Auvi-Q[®]
epinephrine injection, USP
0.1 mg/0.15 mg/0.3 mg auto-injectors



ANAPHYLAXIS DOESN'T WAIT FOR THE SCHOOL NURSE

Teachers, coaches, and staff are called to respond to anaphylaxis at school¹⁻³

AUVI-Q IS DESIGNED TO BE EASY TO USE.



VOICE
INSTRUCTIONS



POCKET-SIZED



AUTO-RETRACTABLE
NEEDLE

Patients should seek emergency medical care immediately after use.

Indication

AUVI-Q[®] (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of anaphylactic reactions or who are at increased risk for anaphylaxis.

Important Safety Information

AUVI-Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care. **In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care.** Each AUVI-Q contains a single dose of epinephrine for single-use injection. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.

Please see additional Important Safety Information on the back, and enclosed full Prescribing Information and Patient Information, or at www.auvi-q.com.

In **2** head-to-head simulated use studies,
inexperienced or untrained users found AUVI-Q easier
to use than EpiPen[®] (epinephrine injection, USP)^{4,5*}

Clinical significance in an actual allergic emergency is unknown.



ELIGIBLE COMMERCIALY INSURED PATIENTS MAY PAY AS LITTLE AS \$0[†] FOR AUVI-Q THROUGH:



HOME DELIVERY:

In EMR, select “ASPN” (mail order pharmacy)



IN-STORE PICKUP:

In EMR, select “Walgreens”

Visit auvi-q.com/hcp/prescribing for more information.

†Terms and Conditions: Only valid for commercially insured patients in the 50 United States and DC through the direct delivery service and/or designated retail pharmacies. Limit two (2) cartons of AUVI-Q per dose, per patient each calendar year. Individual insurance plan requirements may affect the redemption of the offer. **OUT-OF-POCKET COSTS MAY VARY.** Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Vet. Aff., Dept. of Def., or Tricare, and where prohibited by law. OFFER IS NOT INSURANCE. Offer cannot be sold, purchased, traded, transferred, and cannot be combined with any other offer. Cash discount cards are not commercial payers and are not eligible to be used for this program. Offer provided by kaléo, and it may change at any time without notice. Call 844-357-3968 for questions regarding offer eligibility.

Important Safety Information (cont'd)

AUVI-Q should **ONLY** be injected into the anterolateral aspect of the thigh. Do not inject intravenously, or into buttock, digits, hands, or feet. Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Please see enclosed full Prescribing Information and Patient Information, or at www.auvi-q.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Hogue SL, Muniz R, Herrem C, Silvia S, White MV. Barriers to the administration of epinephrine in schools. *J Sch Health*. 2018;88(5):396-404. 2. Nowak-Wegrzyn A, Conover-Walker MK, Wood RA. Food-allergic reactions in schools and preschools. *Arch Pediatr Adolesc Med*. 2001;155(7):790-795. 3. Hogue SL, Goss D, Hollis K, Silvia S, White MV. Training and administration of epinephrine auto-injectors for anaphylaxis treatment in US schools: results from the EpiPen4Schools[®] pilot survey. *J Asthma Allergy*. 2016;9:109-115. 4. Kessler C, Edwards E, Dissinger E, Sye S, Visich T, Grant E. Usability and preference of epinephrine auto-injectors: Auvi-Q and EpiPen Jr. *Ann Allergy Asthma Immunol*. 2019;123(3):256-262. 5. Camargo CA Jr, Guana A, Wang S, Simmons FE. Auvi-Q versus EpiPen: preferences of adults, caregivers, and children. *J Allergy Clin Immunol Pract*. 2013;1(3):266-272.e1-e3.

*Data from 2 open-label, cross-over, simulated use studies with N = 96 and N = 338 inexperienced epinephrine auto-injector users. Studies were sponsored by the manufacturer.